Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research collaboration may initiate up to seven oncology ...
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...
Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses AI and experimental biology to discover new treatments for diseases. The company has a technology platform called ...
Recursion Pharmaceuticals, Inc ( (RXRX)) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc presented to its investors. Recursion Pharmaceuticals, Inc.
Nvidia's equity portfolio ballooned beyond $100 million in the fourth quarter, requiring public disclosures. Just two stocks make up nearly all of its portfolio. Recursion Pharmaceuticals is a small ...
Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of Recursion. And I'm excited to share with you today some of the latest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results